Calcimedica, INC Form 4 insider transactions

CalciMedica, Inc. reports that Director Evgeny Zaytsev acquired stock options for 20,000 shares.

Fred A. Middleton, a Director and 10% Owner of CalciMedica, Inc., acquired 248,972 shares of common stock on June 25, 2026, through a Securities Purchase Agreement.

CalciMedica Chief Medical Officer Sudarshan Hebbar acquired 124,486 shares of common stock.

CalciMedica Director Robert N. Wilson acquired over 1.1 million shares of common stock in a private placement.

Eric W. Roberts, a Director and Chief Business Officer of CalciMedica, Inc., acquired 186,729 shares of common stock on June 25, 2026, through a Securities Purchase Agreement.

CalciMedica CEO Rachel Leheny acquired 186,729 shares of common stock in a private placement transaction on June 25, 2026.

CalciMedica, Inc. reports that Chief Financial Officer Stephen Bardin acquired employee stock options on April 5, 2026.

CalciMedica, Inc. (CALC) insider Sudarshan Hebbar reports on stock option transactions, detailing vesting schedules and potential future equity.

Eric W. Roberts, a Director and Chief Business Officer of CalciMedica, Inc., acquired employee stock options.

Michael J. Dunn, President and COO of CalciMedica, Inc., reported a transaction involving employee stock options.

CalciMedica, Inc. reports on stock option transactions by Chief Scientific Officer Kenneth A. Stauderman.

CalciMedica CEO Rachel Leheny reports the grant of employee stock options, with vesting contingent on an S-8 filing.

CalciMedica Director Alan Glicklich was granted 937 stock options with an exercise price of $3.26, vesting monthly starting October 1, 2025, under a 10b5-1 plan.

CalciMedica's Chief Business Officer, Eric W. Roberts, has filed a Form 4 indicating a planned purchase of 2,500 shares of common stock on September 18, 2025.

CalciMedica's Chief Business Officer, Eric W. Roberts, acquired 3,400 shares of common stock, signaling confidence in the company.

CalciMedica insider Eric W. Roberts discloses a planned acquisition of 5,000 shares of common stock for $3.12 per share on September 12, 2025.

CalciMedica's Chief Business Officer, Eric W. Roberts, acquired 2,343 shares of common stock through a Roth IRA at a weighted average price of $3.1488.

CalciMedica's Chief Business Officer, Eric W. Roberts, increased his beneficial ownership through open market purchases of common stock.

CalciMedica's Chief Business Officer and Director, Eric W. Roberts, increased his beneficial ownership by purchasing 3,508 shares of common stock.

CalciMedica's Chief Business Officer, Eric W. Roberts, increased his beneficial ownership through open market purchases and option exercises.

CalciMedica's Chief Medical Officer, Sudarshan Hebbar, purchased 9,563 shares of common stock at an average price of $2.8194.

CalciMedica's Chief Business Officer, Eric W. Roberts, increased his beneficial ownership through a direct purchase of common stock.

CalciMedica's Chief Medical Officer, Sudarshan Hebbar, acquired additional common stock in open market transactions.

CalciMedica's Chief Scientific Officer, Kenneth A. Stauderman, reported recent stock transactions, including a sale by his spouse that resulted in a short-swing profit violation requiring repayment to the company.

CalciMedica's Chief Business Officer, Director, and 10% Owner, Eric W. Roberts, acquired 1,500 shares of common stock, signaling increased insider confidence.

CalciMedica's Chief Business Officer and Director, Eric W. Roberts, acquired 1,500 shares of common stock, signaling increased insider confidence.

CalciMedica, Inc. CEO and 10% owner Rachel Leheny has filed a Form 4 indicating a planned future purchase of 1,000 shares of common stock at $3.40 per share on July 21, 2025, under a Rule 10b5-1 trading plan.

CalciMedica, Inc. Director Robert N. Wilson acquired 4,500 shares of common stock for $2.87 per share, increasing his direct beneficial ownership to 422,029 shares.

CalciMedica's Chief Business Officer, Eric W. Roberts, a Director and 10% owner, acquired 2,000 shares of common stock at $2.88 per share.

Eric W. Roberts, CalciMedica's Chief Business Officer, Director, and 10% owner, acquired 6,500 shares of common stock, signaling increased insider confidence.